Comparative Pharmacology
Head-to-head clinical analysis: CHOLOVUE versus DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLOVUE versus DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM.
CHOLOVUE vs DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Complexes with anions in the gastrointestinal tract to increase fecal elimination of iodipamide, reducing systemic absorption and enhancing gallbladder visualization.
Radiopaque contrast agent that attenuates X-rays, providing visualization of vascular and urinary structures. It is a high-osmolality ionic dimer that distributes in extracellular fluid and is excreted renally.
100 mg/kg intravenously over 30 minutes every 3-4 weeks.
Intra-arterial or intravenous administration; adult dose varies by procedure: for intravenous urography, 50-100 mL of 60% solution; for CT enhancement, 100-150 mL of 60% solution; maximum total dose 4.2 g iodine/kg body weight.
None Documented
None Documented
Terminal elimination half-life is 6–8 hours in patients with normal renal function; prolonged to 15–20 hours in moderate renal impairment (CrCl 30–50 mL/min) and >24 hours in severe renal failure.
1-2 hours in normal renal function; prolonged in renal impairment (up to 20-30 hours in severe impairment)
Primarily renal; approximately 70% excreted unchanged in urine within 24 hours, with the remainder eliminated as glucuronide conjugates via biliary/fecal route (20%) and minor metabolic pathways (10%).
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent